Effects of intralesional 32-P chromic phosphate in refractory patients with head and neck tumours

Anticancer Research

Volumn 27, Issue 4 C, 2007, Pages 2997-3000

  Alimi, Kyrus A ^a   Firusian, Nosrat ^a   Dempke, Wolfram ^a,b  

^a Elisabeth Hospital   (Germany)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Head and neck cancer; Palliation; Radioisotope therapy

Indexed keywords

BLEOMYCIN; CHROMIUM PHOSPHATE P 32; CISPLATIN; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PHOSPHOCOL; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BURNING SENSATION; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ECHOGRAPHY; ERYTHEMA; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; INJECTION SITE REACTION; PATHOLOGY; PILOT STUDY; PRIORITY JOURNAL; SCINTIGRAPHY; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; TUMOR VOLUME;

ADULT; AGED; CHROMIUM COMPOUNDS; HEAD AND NECK NEOPLASMS; HUMANS; INJECTIONS, INTRALESIONAL; MIDDLE AGED; PHOSPHATES; RADIOPHARMACEUTICALS; SURVIVAL RATE;

EID: 34547789419     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Firusian N and Dempke W: An early phase II study of intratumoral P32 chromic phosphate injection therapy for patients with refractory solid tumors and solitary metastases. Cancer 85: 980-987, 1999.
2. Dempke W and Firusian N: Treatment of malignant pericardial effusion with 32P-colloid. Br J Cancer 80: 1955-1957, 1999.
3. Firusian N, Fricke D and Bocher E: Radionuklidtherapie des Thoraxwandrezidivs des Mammakarzinoms. Tumordiagn Ther 17: 47-57, 1996.
4. Firusian N: Nuklearmedizinische Therapie des fortgeschrittenen therapierefraktären Thoraxwandrezidivs des Mammakarzinoms. Nucl Med 35: 24-28, 1996.
5. Colevas AD: Chemotherapy options for patients with metastatic or recurrent squamous carcinoma of the head and neck. J Clin Oncol 24: 2644-2652, 2006.
6. Bernier J: Head and neck oncology: what the past decade has taught us. Expert Rev Anticancer Ther 9: 1133-1136, 2006.
7. Wong SJ, Machtay M and Li Y: Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone? J Clin Oncol 24: 2653-2658, 2006.
8. Order SE, Siegel JA and Lustig RA: Infusional brachytherapy in the treatment of nonresectable pancreatic cancer: a new radiation modality (preliminary report of the phase I study). Antibody Immunoconjug Radiopharm 7: 11-27, 1994.
9. Werner JA, Kehrl W, Pluzanska A et al: A phase III placebo-controlled study in advanced head and neck cancer using intratumoural cisplatin/epinephrine gel. Br J Cancer 87: 938-944, 2002.
10. Castro DJ, Sridhar KS, Garewal HS et al: Intratumoural cisplatin/epinephrine gel in advanced head and neck cancer: a multicenter, randomized, double-blind, phase III study in North America. Head Neck 25: 717-731, 2003.
11. Duvillard C, Romanet P, Cosmidis A et al: Phase 2 study of intratumoral cisplatin and epinephrine treatment for locally recurrent head and neck tumors. Ann Otol Rhinol Laryngol 113: 229-233, 2004.
12. Vlock DR, Snyderman CH, Johnson JT et al: Phase Ib of the effect of peritumoral and intranodal injections of interleukin-2 in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial. J Immunother Emphasis Tumor Immunol 15: 134-139, 1994.
13. Kitahara S, Ikeda M, Inouye T et al: Inhibition of head and neck metastatic and/or recurrent cancer by local administration of multicytokine inducer OK-432. J Laryngol Otol 110: 449-453, 1996.
14. Allegretti JP and Panje WR: Electroporation therapy for head and neck cancer including carotid artery involvement. Laryngoscope 111: 52-56, 2001.
15. Nemunaitis J, Khuri F, Ganly I et al: Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 15: 289-298, 2001.